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Abstract
Aging is associated with a decline in immune function (immunosenescence), a situation known to
correlate with increased incidence of cancer, infectious and degenerative diseases. Innate, cellular
and humoral immunity all exhibit increased deterioration with age. A decrease in functional
competence of individual natural killer (NK) cells is found with advancing age. Macrophages and
granulocytes show functional decline in aging as evidenced by their diminished phagocytic activity
and impairment of superoxide generation. There is also marked shift in cytokine profile as age
advances, e.g., CD3+ and CD4+ cells decline in number whereas CD8+ cells increase in elderly
individuals. A decline in organ specific antibodies occurs causing reduced humoral responsiveness.
Circulating melatonin decreases with age and in recent years much interest has been focused on
its immunomodulatory effect. Melatonin stimulates the production of progenitor cells for
granulocytes-macrophages. It also stimulates the production of NK cells and CD4+ cells and
inhibits CD8+ cells. The production and release of various cytokines from NK cells and T-helper
lymphocytes also are enhanced by melatonin. Melatonin presumably regulates immune function by
acting on the immune-opioid network, by affecting G protein-cAMP signal pathway and by
regulating intracellular glutathione levels. Melatonin has the potential therapeutic value to enhance
immune function in aged individuals and in patients in an immunocompromised state.
Introduction
Aging is a complex physiological process that involves a
number of biochemical reactions, with molecular changes
that are manifested in single cells as well as in the whole
organism. Aging reflects the sum total of all changes that
occur in living organisms with the passage of time that
lead to functional impairment and increased pathology.
Aging is characterized by a diminished ability to respond
to stress [1]. Among the many theories proposed for
aging, the Oxidative Theory of Aging put forth by Harman
in 1956 [2] has received wide support.
Aging is associated with a decline in immune function
known as immunosenescence. This situation implies
increased susceptibility to infectious diseases and cancer
due to a decreased capacity of the immune system to
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respond to antigenic stimulation [3]. This results in
altered cytokine microenvironment and impairment of
both innate and adaptive immunity [4]. It is interesting to
note that many hormones that are associated with main-
tenance of immune function also decline with advancing
age and the interrelationship between the endocrine sys-
tem and the immune system is considered of crucial
importance in normal human physiology and in mediat-
ing age-associated degenerative diseases [5-8]. The decline
in the production of a number of hormones associated
with aging such as growth hormone (GH), estrogen and
dehydroepiandrosterone, as well as of the pineal sub-
stance melatonin, have been proposed to play a signifi-
cant role in contributing to immunosenesecence [5].
Among these, melatonin has been demonstrated to bear a
general immunoenhancing effect in many animal species
as well as in humans [9].
Melatonin is a natural antioxidant with significant anti-
aging properties [10]. Indeed, any search for a therapeutic
agent that can improve the quality of life in the elderly
implies the identification of substances that have both
antioxidant and immunoenhancing qualities. In this vein,
the role for melatonin has been put forth [11-13] and in
this paper the evidence indicating that melatonin is effec-
tive to combat age associated decline in immune function
will be reviewed with the aim of advocating melatonin as
a possible therapeutic agent for enhancing the quality of
life in the elderly.
Aging and immune function
Immunosenescence is associated with increased incidence
of cancer and of degenerative and infectious diseases. The
progressive functional T cell and B cell deficits may be the
main responsible factors for age-associated disorders
[4,14,15]. The involution of thymus with age results in
alterations of gene expression [16]; indeed, immunose-
nescence is reflected at cellular, molecular and genetic lev-
els [17]. Individuals of the same chronological age may
exhibit variations in the degree of senescence associated
functional impairment [18]. The role of immunity as a
predictor of individual longevity in human beings has
been suggested by several studies like OCTO and NONA
longitudinal studies and they all reveal the existence of
"immunological risk phenotype", that can predict the life
span in the elderly [19].
Aging and innate immunity
Aging affects the innate immune system [20]. In the
innate immune system natural killer (NK) cells play an
important role for inhibiting cancer and metastases.
Longer life in centenarians has been associated with
increased NK cell number, augmented interferon (IFN)-
gamma production and phagocytosis [21-23]. The age-
associated increases in NK cells (21) have been inter-
preted as a compensatory response to overcome the gen-
erally decreased immune function and has been
considered helpful in arresting the growth of neoplastic
cells. For example, in human NK cells from healthy sub-
jects over 90 years of age, the ability to synthesize chemo-
tactic cytokines upon stimulation by IL-12 or IL-2, or to
express the corresponding chemokine receptors are main-
tained (24). However most investigators are of the opin-
ion that functional competence of individual human NK
cells declines with age [21,25]. Indeed, NK cells of aged
people exhibited a diminished production of IFN gamma
and chemokines in response to interleukin (IL)-2 and IL-
6 [25]. Recently, Albright and her coworkers [26] found
severe impairment in the production of mRNA transcripts
representing several cytokines in NK/LAK cells of aged
mouse. The cytotoxic capacity of NK cell is well preserved
in peripheral blood of the centenarians [27].
Functional impairment of macrophages and granulocytes
are reported in the elderly. Diminished intracellular
phagocytic activity, degranulation and decrease in chemo-
tactic and phagocytic activity have all been found in poly-
morphonuclear leukocytes of elderly individuals [24,28].
In a study in centenarians, Miyaji and his coworkers [22]
found that granulocytes exhibited decreased superoxide
production, irrespective of subject's health conditions. A
decrease in superoxide production in elderly subjects has
also been reported in other studies [29-31], the decreased
production of superoxide in the granulocytes being attrib-
uted to the reduction in signal transduction in granulo-
cytes [29]. The attenuation of Fc mediated superoxide
generation and phagocytosis in the elderly has been sug-
gested as the major factor for the age-related decline in
neutrophil function [28,32]. With regard to macrophages,
increased production of proinflammatory mediators like
IL-1, IL-6 and IL-8 occurs in both healthy aged subjects
and people showing pathological aging [33,34]. Macro-
phages are important for phagocytosis and destruction of
microorganisms and also for cytokine production that
regulates the functional ability of other cells of innate
immunity.
Diminished IL-1 levels and diminished generation of
reactive oxygen species (ROS) from monocytes of elderly
subjects has been reported (reviewed by [35]). IL-6 (which
has been termed as a "cytokine for gerontologists", [36])
increases in aged subjects [37,38]. The increase in IL-6
occurs in healthy individuals older than 85 years of age
[39]. The increase in IL-6 seen in aged subjects may con-
tribute to age-ssociated diseases [40] and mortality [41].
Plasma concentrations of soluble intercellular adhesion
molecule-1 (ICAM-1) increased with age [39,42,43]. Col-
lectively, the results suggest that it is this shift in cytokine
profile that is largely responsible for triggering immu-Immunity & Ageing 2005, 2:17 http://www.immunityageing.com/content/2/1/17
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nosenescence and increased morbidity and mortality in
the elderly [39].
Aging and humoral immunity
Aging results in changes in humoral immunity such as an
increase in the levels of serum immunoglobulins like IgA
and IgG, and decrease in the number of B and T lym-
phocytes [44,45]. A decline in organ specific autoantibod-
ies together with an increase in non-organ specific
autoantibodies have been found in the elderly [46].
Reduction in CD 27+ memory B cells has been reported
and this correlated with low T cell number [47]. A
decrease in CD5+ B cells independent of T cell decline was
also reported in aging [48]. Therefore, the reduced
humoral responsiveness and altered antibody-mediated
defense mechanisms seen in aged individuals are
explained mainly by an intrinsic primary cell deficit [49].
The ability of T cells to promote B-cell activation and anti-
body production may be compromised in elderly individ-
uals, as suggested by studies using cytometric phenotypic
analysis [50]. A significant decrease in IL-2 production
with aging plays a role in reducing antibody production
[23,49].
Aging and cellular immunity
Aging not only causes changes in innate immunity and
humoral immunity, but also causes changes in cellular
immunity. A significant decrease in CD3+, CD4+, CD8+
cells and naïve T lymphocytes (CD45RA+CD4+) occurs
with increase in age. An extensive review on T cell function
in aging was published by Pawelec et al. [14]. With aging,
alterations in signal transduction may also occur. The age-
associated decline in T cell function is preceded by involu-
tion of the thymus [35]. The striking feature of T cell alter-
ations in aging is the marked shift from naive to memory
cells with an imbalance of virgin and memory cells being
noted especially in CD8+ T lymphocytes [45]. Naïve T
cells, which are concerned with the mounting primary
immune response, are dependent upon CD28, a co-stim-
ulatory signal for their proliferation [45]. Both the
decrease in the number of naïve T cells and in their
responsiveness with aging cause the decline of specific
immunization response in aged individuals [51]. Large
increases in CD8+ T cells with receptors for single epitopes
of cytomegalovirus are common in the elderly [52]. Lon-
gitudinal studies (OCTO) suggest that the cluster of
immune parameters like low CD4+ cells, an increase in
CD8+ cells and a low IL-2 production are all predictive of
mortality [53-55]. The decline in naïve T cells is one of the
factors that cause a decreased IL-2 production[56].
Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is formed
mainly in the pineal gland of most mammals including
man [57]. In the pineal gland, serotonin is converted in to
melatonin through a two-step enzymatic process involv-
ing N acetylation followed by O-methylation. In humans,
plasma melatonin level begins to increase steadily after
1900 h to 2300 h to attain the peak values at around 0200
– 0400 h [7]. The study of plasma melatonin among sub-
jects of different age groups reveals a consistent decrease
as aging progresses. With some exceptions [58,59] the
decline of melatonin with age has been repeatedly
reported [60-66]. The melatonin day/night rhythm has
been found altered with phase advance in the elderly as
compared to young women [67]. Great variations in the
amplitude of nocturnal melatonin secretions are found
among individuals suggesting that some individuals pro-
duce significantly less melatonin during lifetime than oth-
ers; this may have an impact in terms of aging [7,68]. The
loss of amplitude of melatonin rhythm in the advanced
age is both an indication as well as a cause of age-related
disturbances in the circadian pacemaker leading to
chronobiological disorders [69]. This is accompanied by a
general deterioration of cognitive, psychological and
social functioning as well as by sleep disturbances [70-
72].
The age-related impairment of the immune system first
appears around 60 years of age coinciding with the
decrease of plasma melatonin concentration. Indeed,
melatonin has a defined immunomodulatory role both in
animals and humans [13,73]. The diurnal and seasonal
changes in the immune system have been shown to corre-
late with melatonin synthesis and secretion [74]. Mela-
tonin is synthesized by human lymphocytes and this
finding adds further support to the hypothesis that mela-
tonin plays a role in the regulation of human the immune
system [75].
Melatonin receptors
Melatonin exerts its many physiological actions by acting
on membrane and nuclear receptors although many of its
actions are receptor-independent (e.g., scavenging of free
radicals, interaction with cytosol proteins like calmodu-
lin). The two melatonin receptors cloned (MT1 and MT2)
are membrane receptors that have seven membrane
domains and belong to the superfamily of G-protein cou-
pled receptors [76]. Melatonin receptor activation induces
a variety of responses that are mediated both by pertussis-
sensitive and insensitive G proteins [77]. In the cytosol
melatonin interacts with calmodulin [78]. Nuclear bind-
ing receptors have been identified in human lymphocytes
and monocytes [79].
Melatonin and immune function
In recent years much attention has been devoted to the
possible interaction between melatonin and the immune
system [13,73,80]. Melatonin has significant immu-
nomodulatory roles in immunocompromised states. InImmunity & Ageing 2005, 2:17 http://www.immunityageing.com/content/2/1/17
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1986, Maestroni et al. first showed that inhibition of
melatonin synthesis causes inhibition of cellular and
humoral responses in mice [81]. Mice kept under constant
light, or receiving injections of betaadrenergic blockers
(propranolol) to inhibit melatonin synthesis, exhibited
an inability to mount a primary antibody response to
sheep red blood cells (SRBC), a decreased cellularity in
thymus and spleen and a depressed autologous mixed
lymphocyte reaction; all these were reversed by melatonin
administration at the late afternoon [81]. Late afternoon
injection of melatonin increases both the primary and sec-
ondary antibody responses to SRBC [82]. Indeed, the
immunoenhancing effect of melatonin was evident only
when melatonin was administered in the afternoon or in
the presence of T-dependent antigenic stimulation. Since
melatonin was ineffective in vitro, Maestroni and co-
workers concluded that it exerts its immunostimulating
effect through other neuroendocrine mechanisms in anti-
gen-activated cells [83]. Hamsters exposed to short pho-
toperiods had increased spleen weight and number of
splenic lymphocytes and macrophages [84]. A key find-
ing-albeit in young adult humans – with respect to the
interplay of melatonin and the immune system, was the
observation that the nocturnal rise of blood melatonin in
humans correlated with the increase of thymic production
of peptides like thymosin-1 alpha and thymulin [85].
Melatonin and innate immunity
A number of studies support the immunoregulatory
action of melatonin on the body's innate immunity [80].
Melatonin stimulates the production of progenitor cells
for granulocytes and macrophages (GM-CFU) and has a
general stimulatory action on hemopoiesis [86,87]. Mela-
tonin receptors are detectable in monocyte/macrophage
lineage [79] and melatonin binding to these receptors
stimulates the production of GMCFU cells [88,89]. A
recent pivotal study, although carried out in young adult
mice, has revealed a profound, time-dependent influence
of melatonin on certain cells fundamentally important to
the immune system. Exogenous melatonin augments NK
cells and monocytes in both the bone marrow and the
spleen with a latency of 7 to 14 days [90]. As both these
cells are components of the non-specific immune system,
the findings suggest that melatonin could be an effective
way for arresting neoplastic growth and for destroying
virus infected cells. The action of melatonin on monocyte
production can be partly due to its direct action on mela-
tonin receptors or may be due to an increase of monocyte
sensitivity to stimulants like IL-3, IL-4, IL-6 or GM-colony
stimulating factor (GM-CSF) [88-90]. As stromal cells
contain receptors for kappa opioid cytokine peptides,
melatonin-induced release of opioid peptides from these
stromal cells in bone marrow could be involved in the reg-
ulation of hemopoietic cell proliferation [91]. In addition
to monocytes, the bone marrow precursor cells for the
granulocyte lineage increase in absolute numbers after
melatonin administration. The study of Currier et al. [90]
revealed that melatonin increases the actual production of
the GM-cell lineage and not the inter-organ trafficking of
myeloid precursors. An increased activation of mono-
cytes/macrophages by melatonin has been reported in yet
another study in rodents [92]. As both macrophage cells
and neutrophils form important components of the
innate immune system, the stimulatory action of mela-
tonin reflects a significant immunoenhancing property.
Melatonin treatment restores the decreased total leuko-
cyte count in peripheral blood and bone marrow of pine-
alectomized squirrels [93]. Macrophages have been
shown to form large amounts of nitric oxide (NO) upon
activation by ROS that mediate their microbiocidal prop-
erties. This excessive production of NO can be harmful to
the body as it can result in the development of degenera-
tive diseases [94]. In a recent study melatonin was found
to decrease NO concentration in macrophages by sup-
pressing inducible NO synthase expression [95]. When
melatonin's effects on phagocytic activity of macrophages
were tested at different concentrations, the greatest phago-
cytic stimulation was obtained when melatonin was
added resembling the unstressed situation [96].
NK cells play an important role in immunosurveillance
against neoplasia and virus infected cells [97,98]. IFN-
gamma enhances NK cell activity [99]. An observation of
potentially high prophylactic significance, was the dem-
onstration that exogenous melatonin given acutely at
1800 h to young healthy males increased their responsive-
ness to IFN while the chronic administration of melatonin
augmented the spontaneous NK cell activity and also the
circulating number of NK cells [100]. The increased NK
cell number brought about by melatonin administration
was attributed partly to the increased production of
cytokines by melatonin-stimulated T helper cells. IL-2, IL-
6, IL-12 and IFN-gamma have all been suggested as the
possible cytokines that mediate melatonin-induced
increase of NK cell number [90]. T helper cells contain
melatonin receptors that presumably mediate melatonin
action in releasing cytokines [101-103].
Melatonin and cytokine production
Melatonin has been proposed to regulate the immune sys-
tem by affecting cytokine. production in immunocompe-
tent cells [104]. Melatonin enhances the production of
IL2, IFN-gamma and IL-6 by cultured human mononu-
clear cells [101]. Melatonin, by. activating monocytes
[105], increases the production of IL-1, IL-6, TNF-alpha
and ROS. Melatonin also increases IL-12 production by
monocytes [105]. Repeated stimulation of T helper (Th)
cells in the presence of IL-12 causes Th cells to differenti-
ate into Th1 cells, which produce IL-2 and IFN-gamma
and are particularly effective in enhancing immuneImmunity & Ageing 2005, 2:17 http://www.immunityageing.com/content/2/1/17
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responses that involve macrophages and other phago-
cytes. Melatonin augments IFN-gamma production by
Th1 cells [104]. The enhancement of NK cell activity by
melatonin is attributed to the increased production of IL-
2 and IL-12 [104,106,107].
Human lymphocytes themselves play an important role
in stimulating IL-2. production in an autocrine or para-
crine fashion [75]. After melatonin treatment, up-regula-
tion of gene expression for TGF-β, M-CSF, TNF-α, and
stem cell factor (CSF) in peritoneal exudate cells, and the
level of gene expression of IL-1β, M-CSF, TNF-α, IFN-γ,
and SCF in splenocytes were reported [108]. Melatonin's
immunoenhancing effect depends upon its ability to
enhance the production of cytokines as well as its anti-
apoptotic and antioxidant action. As a functional impair-
ment of macrophages and granulocytes (as shown by the
diminished intracellular phagocytic activity, degranula-
tion and decrease in chemotactic activity) has been
reported in the elderly [28,44] and a parallel decrease in
melatonin production occurs [60-66] it may not be unrea-
sonable to speculate that immunosenescence can be
partly attributed to a decreased production of melatonin.
To restore the defective phagocytic function the use of
adjuvants with immunizations and nutritional supple-
ments has been proposed [109].
Micronutrients like zinc, selenium and vitamin E play a
vital role in phagocytic function [110]. Since melatonin
can stimulate the immune response and correct immuno-
deficiencies by causing up-regulation of cytokine produc-
tion it can be used therapeutically for correcting the
immunodeficiency state associated with aging.
Melatonin and cellular and humoral immunity
Besides its stimulatory action on the production of several
cytokines that regulate immune function, melatonin's
immunoenhancing properties have been attributed to a
direct action on the immunocompetent cells (e.g. granu-
locyte-macrophage cells, NK cells and lymphocytes). Ear-
lier studies demonstrated that the thymus is a primary
target of melatonin's action. The thymus is an organ of
youth in mammals, yet any influences on the thymus in
youth will have profound effects on the immune system
of elderly mammals. A milestone, earlier demonstration
revealed that pinealectomized, young mice underwent
accelerated involution of the thymus [111]. The presence
of melatonin binding sites in membrane preparations of
non-mammalian (duck) thymus has also been reported
[112]. Mice kept under constant light, or administered
with beta-adrenergic blockers exhibited decreased cellu-
larity of thymus and spleen that was reversed by late after-
noon administration of exogenous melatonin
[81,82,113].
The severe loss of thymocytes with age is the main cause
of structural thymic atrophy and thymic weight loss.
Melatonin administration increased the total number of
thymocytes in old mice [114]. In that study, thymic cell
number in 2 months-old mice was 12.6 × 107, while it
dropped to 7.3 × 107 cells in 24 months-old animals; in
melatonin treated old mice the total number of thymo-
cytes was 9.1 × 107 cells [114]. This protective effect of
melatonin on thymocytes was attributed to its antiapop-
totic action. Melatonin inhibited glucocorticoid- or
hydroxyl radical-induced thymic apoptosis [115,116].
The reversal of age-associated thymic involution by mela-
tonin added further support to the concept that melatonin
can be a potential therapeutic agent for correcting immu-
nodeficiency state associated with aging and possibly
other immunocompromised states like severe stress [117].
Finally, Yu et al. [118] have demonstrated that orally
administered melatonin can substantially promote the
survival (anti-apoptosis) of precursor B lymphocytes
(responsible for humoral immunity) in the B lymphocyte
generating site, i.e., the bone marrow. This indicates that
melatonin treatment can boost the survival of mature B
cells which are the functional elements in humoral immu-
nity.
Melatonin and T lymphocyte function
Melatonin enhances both cell-mediated and humoral
immunity. The administration of melatonin to normal or
immunocompromised mice elevated in vitro and in vivo
antibody responses [73]. The immunoenhancing effect of
melatonin involves opiod peptides; melatonin stimulates
Th cells to secrete opiod peptides that have upregulatory
effects on a variety of immune cells [73]. According to
Nelson and Drazen [119], melatonin is a part of a com-
plex physiological system that coordinates reproductive,
immunological and other physiological processes to cope
up with energetic stressors during winter. Studies in birds
also indicate that melatonin stimulates both cellular and
humoral responses and that the response involves opiate
intermediates [120,121].
The immunostimulatory role of melatonin is exerted
mainly on Th cells and on T lymphocyte precursors. There
is a possibility that melatonin could act as an autocoid in
bone marrow as shown by the demonstration of mela-
tonin synthesis in bone marrow cells of mice and humans
[122]. The existence of specific melatonin binding sites
inlymphoid cells provides evidence for a direct effect of
melatonin in the regulation of the immune system. By
using the melatonin agonist 2 [125I]-melatonin high affin-
ity binding sites and a signal tranduction pathway for
melatonin have been characterized in human lym-
phocytes [123,124]. Melatonin also counteracted the
inhibitory effect of prostaglandin E2 on IL-2 production
in human lymphocytes via its MT1 membrane receptorImmunity & Ageing 2005, 2:17 http://www.immunityageing.com/content/2/1/17
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[125]. Melatonin augments CD4+ lymphocytes and
decreases CD8+ lymphocytes in rat submaxillary lymph
nodes [126]. Collectively, these studies indicate that mela-
tonin possesses important immunoenhancing properties
and suggest that melatonin may favor a Th-1 response.
During the natural history of human immunodeficiency
virus type I (HIV-1) infection, an impairment of IL-12
production precedes a switch from a Th-1 to a Th-2 stage
of cellular immunity. A recent study indicated a correla-
tion of serum levels of melatonin and IL-12 in a cohort of
77 HIV-1 infected individuals, the decreased levels of
serum melatonin found in HIV-1-infected individuals
being possibly instrumental in the impairment of Th-1
immune response [127].
Besides the release of proinflammatory Th-1 cytokines,
such as IFN-gamma and IL2 administration of melatonin
to antigen-primed mice increased the production of IL10,
indicating that melatonin can also activate anti-inflam-
matory Th-2-like immune responses in certain circum-
stances [128]. Therefore, it is not yet clear whether
melatonin acts only on Th-1 cells or also affects Th-2 cells.
This is an important subject as the Th-1/Th-2 balance is
significant for the immune response [73]. Relevant to this,
melatonin treatment suppressed the subsequent in vitro
stimulation by the mitogenic agents LPS (that stimulates
B cells) and Con A (that stimulates T cells) in submaxillary
lymph nodes [126]. In addition, an inhibitory influence
of melatonin on parameters of the immune function has
also been demonstrated, i.e., in human NK cell activity,
DNA synthesis, IFN-gamma and TNF-alpha synthesis, as
well as the proliferation of T lymphocytes and lymphob-
lastoid cell lines were depressed by melatonin [73]. Mela-
tonin can correct immunodeficiencies secondary to acute
stress, viral diseases and drug treatment. In immunode-
pressed conditions, the immunoenhancing action of
melatonin seems to be restricted to T lymphocyes [129].
In conditions of immunodeficiency, as in other patholo-
gies and the normal, melatonin appears to favour a Th1
lymphocyte response [108]. Finally, a recent study (130)
has estabished a significant role for melatonin, i.e., as an
adjuvant with vaccination in sheep afflicted with ovine
footrot, indicating that this agent clearly has significant
benefits in health maintenance and disease treatment.
Mechanism of action of melatonin in immune 
responses
Studies by Drazen and Nelson [102] indicated that mela-
tonin receptor subtype MT2 but not MT1, is involved in
melatonin-induced enhancement of cell-mediated and
humoral function in mice. cAMP signal transduction
plays an important role in regulating lymphocyte function
and this pathway appeared to be abnormal in aged
mice[131]. Melatonin antagonized partially forskolin-
induced increase of cAMP levels of lymphocytes; indeed,
G1 protein coupled adenylate cyclase-cAMP signal path-
way may be one of the important mechanisms for the
anti-inflammatory immunoregulation by melatonin
[132]. Melatonin enhanced significantly met-enkephalin
in 2 and 11 months old mice, and the effect was blocked
by nifedipine, a Ca2+ antagonist [132]. This suggests that
melatonin promotes the production of met-enkephalin
through L-type Ca2+ channel. Melatonin-induced immu-
noregulation may depend upon immuno-opiod interac-
tion [133].
It has been suggested that Th-1 responses are readily trans-
formed into Th-2 dominance through depletion of intrac-
ellular GSH [134]. GSH in its reduced form is the single
most important protective and regulatory antioxidant in
cells. The work of Peterson and his coworkers [135]
showed that depletion of glutathione from antigen pre-
senting cells in vivo resulted in lowered Th-1 activity and
higher Th-2 activity. Murata et al. [136,137] showed that
oxidized macrophages exhibited higher levels of oxidized
glutathione as they polarized to type Th-2 cells. Thus the
immune activity can have Th-1 or Th-2 characteristics
depending upon the relative antioxidant status of the
cells.
Since melatonin stimulates the production of glutathione
[138] its immunoenhancing role may be partly due to its
influence on the maintenance of intracellular glutathione
level. Indeed, melatonin acts as a hypnotic-chronobiotic
[139,140] with cytoprotective properties [141,142] as
well as an immunoenhancing agent. Indeed, melatonin
not only acts as a hypnotic-chronobiotic with cytoprotec-
tive properties but also as an immunoenhancing agent.
Melatonin provides a functional link between the neu-
roendocrine and immuno-hematopoietic systems [143].
Recent studies reveal that not only melatonin but also its
oxidation product N1 acetyl-N2-formyl-5-methox-
ykynuramine (AFMK) is very effective in acting onneu-
trophils [144,145]. Both melatonin and AFMK have been
shown to inhibit IL-8 release from neutrophils and AFMK
has been found to be more active than melatonin in this
aspect. The production of TNF-alpha by neutrophils is
also inhibited by melatonin and AFMK. Since TNF-alpha
and IL-8 contribute to the severity of inflammatory condi-
tions [146], the finding of melatonin inhibiting the
release of IL-8 and TNF-alpha assumes significance for it
may help to reduce acute and chronic inflammation. Neu-
trophils are more responsive than monocytes to AFMK
suggesting that melatonin biosynthesis and metabolism
participate in the chemical communication among leuko-
cytes. Melatonin may be effective in optimizing intrinsic
immune responses rather than acting simply as an anti-
oxidant [147]. Dietary supplementation of melatonin has
been shown to change mRNA levels of many genes and toImmunity & Ageing 2005, 2:17 http://www.immunityageing.com/content/2/1/17
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arrest the attenuated immune responses associated with
senescence [147].
Melatonin and season-dependent immune 
function
A number of recent studies point out that seasonal
changes exert influence on immune function and mela-
tonin may play an important role in this aspect. Seasonal
changes of immune function in animals are mediated by
the duration of melatonin secretion, which acts as a pho-
toperiodic signal [119]. Such seasonal changes in immune
function have been observed in humans also. Increased
production of proinflammatory cytokines IFN-gamma
and alpha occurred during winter [148]. Highest produc-
tion of IL-6 was reported in healthy volunteers during
autumn/winter season [149]. In humans the seasonal
changes in immune functions can be mediated by the
changes in duration of melatonin secretion. Seasonal
changes in cytokines like IL-6, IFN-alpha, IFN or the bal-
ance of Th-1 and Th-2 response can account for seasonal
changes in mood and behavior, such as Seasonal Affective
Disorder.
Summary
The age-associated decline in immune function, known as
immunosenescence, is characterized by a decrease in the
functional activity of NK cells, granulocytes and macro-
phages. There is significant reduction in IL-1 and dimin-
ished generation of ROS from monocytes. In addition,
there is an increase of IL-6 production. Besides causing
changes in innate immunity, aging is associated with
changes in cellular and humoral immunity. Decreases of
CD3 and CD4 and increases of CD8 cells occur in elderly
individuals. The decrease in IL-2 production that occurs
during aging causes a reduced antibody formation. Mela-
tonin seems to play a significant immunomodulatory
role. Melatonin enhances both innate and cellular immu-
nity. It stimulates the production of progenitor cells of
granulocytes and macrophages and of NK cells. Produc-
tion of IL-2, IL-6 and IL-12 is stimulated by melatonin.
Increased T-helper production, particularly of CD4+ cells,
occurs after melatonin supplementation. Melatonin
decreases CD8+ cells. Melatonin may act through the
immune-opiod network. The regulation of immune func-
tion by melatonin appears to involve cAMP signal trans-
duction, L-type Ca2+ channels and glutathione. The
seasonal changes in immune function observed in ani-
mals and humans are likely to be mediated by the changes
in the duration of melatonin secretion.
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